Phase II study of amonafide in advanced pancreatic adenocarcinoma

Kaye Linke, Richard Pazdur, James L. Abbruzzese, Jaffer A. Ajani, Rodger Winn, James E. Bradof, Karen Daugherty, Bernard Levin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

Original languageEnglish (US)
Pages (from-to)353-356
Number of pages4
JournalInvestigational New Drugs
Volume9
Issue number4
DOIs
StatePublished - Nov 1 1991

Fingerprint

amonafide
Adenocarcinoma
Agranulocytosis
Exanthema
Nausea
Vomiting
Appointments and Schedules
Drug Therapy

Keywords

  • amonafide
  • pancreatic carcinoma
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Linke, K., Pazdur, R., Abbruzzese, J. L., Ajani, J. A., Winn, R., Bradof, J. E., ... Levin, B. (1991). Phase II study of amonafide in advanced pancreatic adenocarcinoma. Investigational New Drugs, 9(4), 353-356. https://doi.org/10.1007/BF00183580

Phase II study of amonafide in advanced pancreatic adenocarcinoma. / Linke, Kaye; Pazdur, Richard; Abbruzzese, James L.; Ajani, Jaffer A.; Winn, Rodger; Bradof, James E.; Daugherty, Karen; Levin, Bernard.

In: Investigational New Drugs, Vol. 9, No. 4, 01.11.1991, p. 353-356.

Research output: Contribution to journalArticle

Linke, K, Pazdur, R, Abbruzzese, JL, Ajani, JA, Winn, R, Bradof, JE, Daugherty, K & Levin, B 1991, 'Phase II study of amonafide in advanced pancreatic adenocarcinoma', Investigational New Drugs, vol. 9, no. 4, pp. 353-356. https://doi.org/10.1007/BF00183580
Linke, Kaye ; Pazdur, Richard ; Abbruzzese, James L. ; Ajani, Jaffer A. ; Winn, Rodger ; Bradof, James E. ; Daugherty, Karen ; Levin, Bernard. / Phase II study of amonafide in advanced pancreatic adenocarcinoma. In: Investigational New Drugs. 1991 ; Vol. 9, No. 4. pp. 353-356.
@article{ae7258c517bf474eb35e33c74c955f6c,
title = "Phase II study of amonafide in advanced pancreatic adenocarcinoma",
abstract = "To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.",
keywords = "amonafide, pancreatic carcinoma, phase II",
author = "Kaye Linke and Richard Pazdur and Abbruzzese, {James L.} and Ajani, {Jaffer A.} and Rodger Winn and Bradof, {James E.} and Karen Daugherty and Bernard Levin",
year = "1991",
month = "11",
day = "1",
doi = "10.1007/BF00183580",
language = "English (US)",
volume = "9",
pages = "353--356",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Phase II study of amonafide in advanced pancreatic adenocarcinoma

AU - Linke, Kaye

AU - Pazdur, Richard

AU - Abbruzzese, James L.

AU - Ajani, Jaffer A.

AU - Winn, Rodger

AU - Bradof, James E.

AU - Daugherty, Karen

AU - Levin, Bernard

PY - 1991/11/1

Y1 - 1991/11/1

N2 - To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

AB - To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

KW - amonafide

KW - pancreatic carcinoma

KW - phase II

UR - http://www.scopus.com/inward/record.url?scp=0026355178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026355178&partnerID=8YFLogxK

U2 - 10.1007/BF00183580

DO - 10.1007/BF00183580

M3 - Article

C2 - 1804812

AN - SCOPUS:0026355178

VL - 9

SP - 353

EP - 356

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -